Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VKORC1 | Q9BQB6 | 2/20 | 0.82 |
| ▸ | NQO1 | P15559 | 7/20 | 0.69 |
| ▸ | TOP1 | P11387 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.68 |
| ▸ | CRHBP | P24387 | 1/20 | 0.68 |
| ▸ | CASP7 | P55210 | 1/20 | 0.68 |
| ▸ | CASP6 | P55212 | 1/20 | 0.68 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32659670 | 1.00 | VKORC1 (0.82) | VKORC1NQO1TOP1CYP2C9CRHBP | |
| SCHEMBL7349603 | 0.91 | VKORC1 (1.00) | VKORC1NQO1TOP1CYP2C9CRHBP | |
| SCHEMBL14078661 | 0.90 | NQO1 (0.73) | VKORC1NQO1TOP1CYP2C9CRHBP | |
| SCHEMBL18126686 | 0.86 | NQO1 (0.78) | VKORC1NQO1TOP1CYP2C9CRHBP | |
| SCHEMBL14172134 | 0.85 | NQO1 (0.68) | VKORC1NQO1TOP1CYP2C9CRHBP | |
| SCHEMBL8868322 | 0.84 | VKORC1 (0.69) | VKORC1NQO1CYP2C9 | |
| SCHEMBL8469143 | 0.84 | VKORC1 (0.78) | VKORC1NQO1TOP1CYP2C9CRHBP | |
| SCHEMBL14078663 | 0.84 | CYP2C9 (0.72) | VKORC1NQO1TOP1CYP2C9CRHBP | |
| SCHEMBL28761758 | 0.84 | VKORC1 (0.69) | VKORC1NQO1TOP1CYP2C9CRHBP | |
| SCHEMBL8042698 | 0.83 | CYP2C9 (0.86) | VKORC1NQO1TOP1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 566 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021042001-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | Natural Extraction Systems, LLC (US) | 2021-03-04 | — | — | WO | claimed |
| EP-2611466-A2 | SHEAR CONTROLLED RELEASE FOR STENOTIC LESIONS AND THROMBOLYTIC THERAPIES | President and Fellows of Harvard College (US) | 2013-07-10 | — | — | EP | claimed |
| WO-2012074588-A2 | SHEAR CONTROLLED RELEASE FOR STENOTIC LESIONS AND THROMBOLYTIC THERAPIES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-06-07 | — | — | WO | claimed |
| US-8034119-B2 | Delivering an agent to a patient's body | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2011-10-11 | — | — | US | claimed |
| US-20050031577-A1 | Therapeutic polyesters and polyamides | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2005-02-10 | — | — | US | claimed |
| US-20040127996-A1 | Delivering an agent to a patient's body | BOSTON SCIENTIFIC SCIMED, INC. | 2004-07-01 | — | — | US | claimed |
| EP-1387649-A1 | DELIVERING AN AGENT TO A PATIENT'S BODY | SciMed Life Systems, Inc. (US) | 2004-02-11 | — | — | EP | claimed |
| US-6685745-B2 | Delivering an agent to a patient's body | SCIMED LIFE SYSTEMS, INC. | 2004-02-03 | — | — | US | claimed |
| EP-1309354-A2 | THERAPEUTIC POLYESTERS AND POLYAMIDES | Rutgers, The State University (US) | 2003-05-14 | — | — | EP | claimed |
| US-20020173818-A1 | Delivering an agent to a patient's body | BOSTON SCIENTIFIC SCIMED, INC. | 2002-11-21 | — | — | US | claimed |
| WO-2002091957-A1 | DELIVERING AN AGENT TO A PATIENT'S BODY | SCIMED LIFE SYSTEM, INC. (US) | 2002-11-21 | — | — | WO | claimed |
| US-20020071822-A1 | Therapeutic polyesters and polyamides | POLYMERIX CORPORATION | 2002-06-13 | — | — | US | claimed |
| WO-2002009768-A2 | THERAPEUTIC POLYESTERS AND POLYAMIDES | RUTGERS, THE STATE UNIVERSITY (US) | 2002-02-07 | — | — | WO | claimed |
| US-4334020-A | Method of producing L-glutamic acid by fermentation | AJINOMOTO COMPANY INCORPORATED (JP) | 1982-06-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | VKORC1 2181/4885NQO1 234/4885TOP1 3440/4885 |
| US-20020071822-A1 | Therapeutic polyesters and polyamides | NPEPPS, PAICS, PUF60 | VKORC1 4089/4885NQO1 3920/4885TOP1 790/4885 |
| US-20050031577-A1 | Therapeutic polyesters and polyamides | NPEPPS, PAICS, PUF60 | VKORC1 3900/4885NQO1 3832/4885TOP1 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.